Fresenius Kabi Takes Control Of mAbxience To Bolster Biosimilars

Also Announces Acquisition Of Ivenix To Strengthen Medtech Business

 
• By David Wallace
  
55% - Red glass text on white background
The deal for a 55% stake in mAbxience includes a put/call option scheme for the remaining 45% • Source: christitzeimaging.com / Alamy Stock Photo
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Deals

More from Business